Navigation Links
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
Date:8/27/2007

al pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

Pfizer Forward-Looking Statement

The information contained in this release is as of August 27, 2007. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a collaboration between Pfizer and Bristol-Myers Squibb with respect to certain product candidates, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates; and competitive developments. There is no assurance that the definitive research, development and commercialization agreement relating to early-stage compounds for the potential treatment of metabolic disorders that is described in this release will result in the discovery, development or commercialization of products.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of products pursuant to a collaboration agreement between BMS and Pfizer. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties,
'/>"/>

SOURCE Bristol-Myers Squibb
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio, Pfizer enter multimillion-dollar research agreement
2. Pfizer-Pharmacia Fallout Gives Celltech A CEO
3. Sale of Norlight Telecommunications is finalized
4. WARF enters licensing agreements for stem cell products
5. Quick peeks, Clawback Agreements, and the rules of electronic discovery
6. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
7. WARF expands license agreement with Advanced Cell Technology
8. Lucigen Corp. enters global licensing agreement
9. GE Healthcare enters agreement with Canadian health authority
10. New angel capital centered on GenTel agreement with big pharma
11. Prodesse enters patent agreement with Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)HOUSTON, Dec. 3 JourneyLite of Houston, LLC announced today that it has updated its facility to offer patients a second surgical option, vertical sleeve gastrectomy , along with the LAP-BAND®
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
Breaking Biology Technology:JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5
...al Branding Strategy, ST. LOUIS, April 30 Sigma-...tegration of its Riedel-de Haen(R),Laboratory Reag... 2008,( http://www.sigma-aldrich.com/rebranding )....e with our products and,services," said Josef Zihl... for the Research Specialties and Research Essenti...
...s,Inc. (Nasdaq: CADX ), a biopharmaceutical compa...alizing proprietary product candidates principally...that the company,s,President and CEO Theodore Schr...w at the following investment conferences:, -- D...t the InterContinental Hotel in Boston on Tues...
...mpany (NYSE: BMY ) invites investors and the gene...eting with stockholders at 10 a.m. ET on Tuesday,M...rd items to be,transacted, senior executives will ... information on how to listen to the webcast, plea...l-Myers Squibb website at, http://www.bms.com/ir ....
Other Biology Technology:Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 2
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Children exposed to secondhand cigarette smoke have an increased risk of developing lung cancer in adulthood, even if they never smoked. , Results of this study are published in Cance
(Date:12/2/2009)PHILADELPHIA New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for ot
Breaking Biology News(10 mins):Grooving down the helix 2Grooving down the helix 3Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cigarette smoking increases colorectal cancer risk 2PDI Reports 2009 Second Quarter Financial Results 13399 1PDI Reports 2009 Second Quarter Financial Results 13399 2PDI Reports 2009 Second Quarter Financial Results 13399 3PDI Reports 2009 Second Quarter Financial Results 13399 4PDI Reports 2009 Second Quarter Financial Results 13399 5PDI Reports 2009 Second Quarter Financial Results 13399 6PDI Reports 2009 Second Quarter Financial Results 13399 7PDI Reports 2009 Second Quarter Financial Results 13399 8PDI Reports 2009 Second Quarter Financial Results 13399 9Orexigen 28R 29 Therapeutics to Speak at Canaccord Adams Global Growth Conference 13397 1ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12 13395 1
...st of its kind study examining the effects of meth...g appears to cause abnormal brain development in c..., 2009, online issue of Neurology , the medical j..."Methamphetamine use is an increasing problem amon...ing number of children with prenatal meth exposure...
... 2009 Immigrant women are less likely to use foli...na bifida, particularly those who recently immigra...y a St. Michael,s Hospital physician in collaborat...University of Toronto. The study is the first to p...cid use in Canada. , "Our study,s findings report...
... Cincinnati (UC) cancer cell biologists have ident...cer susceptibility and development. They say this ...position to develop lung cancer for people with a ...ther investigation, they believe the gene could be...it from earlier, more aggressive lung cancer scree...
Other Biology News:Prenatal meth exposure linked to abnormal brain development 2Immigrant women may be at higher risk of having a baby with a birth defect 2Researchers identify specific lung cancer susceptibility gene 2
...icant secondary structure are often very difficult...ittle or no product. Yield, specificity and consis...g agents in PCR amplification reactions. Polymer-A...ates., Polymer-Aide is designed for molecular bi...
MutaGEL Parodontitis from Alpco Diagnostics
... Enhancer (with betaine) substantially improves PC...specificity for amplification of many DNA template...the base-pair composition dependence of DNA meltin...s pauses of DNA polymerase, and reduces secondary ...
...strip holder is designed for use with any Costar f...ew product number, created to easily match Corning...please order under the old Sigma-Aldrich number (Z...ce. ID clarifier: "egg crate" strip holder Sterili...
Biology Products: